Autolus Revenue and Competitors
Estimated Revenue & Valuation
- Autolus's estimated annual revenue is currently $2.5M per year.
- Autolus's estimated revenue per employee is $5,426
- Autolus's total funding is $631.7M.
- Autolus's current valuation is $321.6M. (January 2022)
Employee Data
- Autolus has 470 Employees.
- Autolus grew their employee count by 16% last year.
Autolus Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.1M | 24 | -11% | N/A | N/A |
#2 | $14.9M | 83 | 5% | N/A | N/A |
#3 | $87.9M | 405 | 25% | $292M | N/A |
#4 | $2.6M | 470 | 16% | $631.7M | N/A |
#5 | $14.9M | 96 | -8% | $81M | N/A |
#6 | $1.2M | 203 | 7% | $460.5M | N/A |
#7 | $44.8M | 231 | 0% | $132.9M | N/A |
#8 | $7.6M | 49 | -37% | N/A | N/A |
#9 | $17.4M | 112 | 12% | N/A | N/A |
#10 | $334.6M | 1349 | 11% | £994.6M | N/A |
What Is Autolus?
Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. We are building a leading biotechnology company focussed on the development and commercialisation of engineered T-cell therapies for haematological and solid tumours. Autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient's own cells.
keywords:N/A
$631.7M
Total Funding
470
Number of Employees
$2.5M
Revenue (est)
16%
Employee Growth %
$321.6M
Valuation
N/A
Accelerator
Autolus's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Director Distribution and Logistics | Reveal Email/Phone |
2 | Executive Director, Financial Reporting and Controls | Reveal Email/Phone |
3 | Director, CAR T Patient and Customer Support | Reveal Email/Phone |
4 | Sr Director, Strategic Site Engagement | Reveal Email/Phone |
5 | Executive Director | Reveal Email/Phone |
6 | Associate Director, MSAT | Reveal Email/Phone |
7 | General Counsel | Reveal Email/Phone |
8 | Chief Financial Officer | Reveal Email/Phone |
9 | Senior Director, Strategic Site Engagement | Reveal Email/Phone |
10 | Director, Financial Planning and Analysis | Reveal Email/Phone |
Autolus News
Autolus Therapeutics plc (NASDAQ:AUTL) Expected to Post Quarterly Sales of $260,000.00. Posted by admin on Apr 16th, 2022.
Autolus Therapeutics reported earnings of ($0.53) per share during the same quarter last year, which indicates a positive year-over-year growth...
Autolus Therapeutics PLC (AUTL) stock has fallen -21.77% over the last 12 months, and the average rating from Wall Street analysts is a...
Blackstone Inc. is investing as much as $250 million in U.K. biotechnology company Autolus Therapeutics PLC to fund the final stages of development of a new therapy to treat a serious form of leukemia, the companies said. Of the total investment, as much as $150 million will support the develop ...
Registered Number 11185179 (England & Wales) Annual Report and Accounts for the year ended 31 December 2020 for Autolus Therapeutics pie AUTOLUS THERAPEUTICS PLC Introduction and Contents Autolus Therapeutics pie (the 'Company', or 'Parent Company') is a public limited company incorporate ...
Other Companies in London
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $179.1M | 470 | 3% | N/A |
#2 | $179.3M | 470 | 6% | N/A |
#3 | $72.8M | 472 | 39% | N/A |
#4 | $126M | 472 | 2% | N/A |
#5 | $156.7M | 473 | 3% | N/A |